drugset / Trial / NCT00749749

Efficacy and Safety of the CollaRx Bupivacaine Implant Compared to the ON-Q Painbuster Following Abdominal Hysterectomy

NCT00749749 ↗

Phase 2 Completed 27 enrolled Innocoll Premier Research · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the CollaRx Bupivacaine Implant is safe and effective in reducing the amount of narcotic pain medication needed to control pain during the first 96 hours after abdominal hysterectomy when compared to the ON-Q PainBuster Post-op Pain Relief System.

Timeline

Start
2008-09-10
Primary completion
2008-12-22
Completion
2008-12-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivacaine Other / unclassified 150 mg Other
Comparator Bupivacaine Other / unclassified 900 mg Other

Indications